Sort   by:  
 Page size 
UnknownPRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing in melanoma.
Not available
S-EPMC10621831 | biostudies-literature
UnknownMelanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
Not available
S-EPMC8504361 | biostudies-literature
UnknownWhole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.
Not available
S-EPMC4359221 | biostudies-literature
UnknownDesmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome.
Not available
S-EPMC5216812 | biostudies-literature
UnknownA novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy.
Not available
S-EPMC6361951 | biostudies-literature
UnknownAdaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma.
Not available
S-EPMC8888590 | biostudies-literature
UnknownCX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.
Not available
S-EPMC7251123 | biostudies-literature
UnknownRegulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
Not available
S-EPMC6731642 | biostudies-literature
UnknownOlutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort.
Not available
S-EPMC12619413 | biostudies-literature
UnknownExperiences of Inuit in Canada who travel from remote settings for cancer care and impacts on decision making.
Not available
S-EPMC8042963 | biostudies-literature
Sort   by:  
 Page size